SATELLOS Announces 2021 Year End Financial Results and Operational Highlights
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
SATELLOS BIOSCIENCE INC. ANNOUNCES SCIENTIFIC RESEARCH AGREEMENT WITH UNIVERSITÉ DE SHERBROOKE TO STUDY RARE MUSCULAR
SATELLOS BIOSCIENCE ANNOUNCES NEW BOARD APPOINTMENTS Satellos welcomes new board members to strengthen its pharmaceutical
SATELLOS BIOSCIENCE REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Satellos positioned to pursue
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES Toronto,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,
Toronto, Ontario -- (August 30, 2021) Satellos Therapeutics Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics
SATELLOS BIOSCIENCE Announces High Resolution Crystal Structure of Duchenne Drug Target TORONTO, ONTARIO –August 26,
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO,